Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 793

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 793
---
 stock on the date of grant (excluding the number of shares of common stock issued under the 2017 Plan and/or the Legacy Plan or subject to outstanding awards granted under the 2017 Plan and/or the Legacy Plan). No award will be granted under the 2017 Plan on, or after, July 7, 2027. Stock options During the six months ended December 31, 2023, a total of 89 stock options to purchase shares of common stock at an exercise price of $4.655 per share were granted to directors and officers of the Company. The 26 options granted to non-employeedirectors vest pro rata monthly over 12 months commencing on December 31, 2023. The remaining 63 options granted to executive officers, employees and consultants vest as to 25% on the first anniversary of grant with the remaining portion vesting pro rata monthly thereafter over 36 months. All of the options to purchase shares of common stock granted have a 10-yearterm and are subject to cancellation upon the grantees’ termination of service for the Company, with certain exceptions. The following table sets forth changes in stock options outstanding under all plans:

| Balance - June 30, 2023     |     | Number of      
 stock options  
 outstanding    
 (in thousands) | 198 |   |     | Weighted 
 average  
 exercise 
 price    |  51.71 |
|:----------------------------|:----|:---------------|----:|:--|:----|:---------|-------:|
| Granted                     |     |                |  89 |   |     |          |   4.66 |
| Expired                     |     |                | (19 | ) |     |          | 140.20 |
| Forfeited                   |     |                | (31 | ) |     |          |   8.26 |
| Balance - December 31, 2023 |     |                | 237 |   |     |          |  32.92 |

The following table summarizes stock options outstanding and exercisable under all plans at December 31, 2023:

|                    | Exercise price 
 $              |     |            Number 
    Outstanding at 
 December 31, 2023 
    (in thousands) |     |     |          Weighted 
 average remaining 
  contractual life 
           (years) |     |     |            Number 
    exercisable at 
 December 31,